MRKR
Marker Therapeutics, Inc.
+0.08 (+7.01%)1.22USD42.0K成交股數20.3M市值–本益比(近四季)5.2股價營收比–營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | 752K+115% | 1.1M-43% | 1.2M+5% | 861K-31% | 349K-67% | 1.9M+648% | 1.2M+53% | 1.2M | 1.1M | 258K | 763K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 1.5M | 2.8M | 2.1M | 2.3M | 4.2M | 3.1M | 3.5M | 2.3M | 2.6M | 2.6M | 2.0M | 2.4M |
| 銷售管理費用 | 1.1M | 1.2M | 847K | 1.0M | 945K | 1.4M | 855K | 1.1M | 1.2M | 1.4M | 1.4M | 2.5M |
| 營業利益 | −2.6M-49% | −4.1M-18% | −674K-72% | −2.1M-7% | −5.1M+101% | −5.0M+69% | −2.4M-25% | −2.3M-44% | −2.5M | −2.9M | −3.2M | −4.1M |
| 營業利益率 | – | -541.8% | -61.1% | -173.3% | -594.8% | -1,420.1% | -124.6% | -197.4% | -204.9% | -278.1% | -1,242.2% | -542.1% |
| 稅後淨利 | −1.8M-55% | −3.2M-28% | −1.7M-26% | −2.0M-9% | −4.0M+68% | −4.4M+59% | −2.3M-23% | −2.2M-187% | −2.4M | −2.8M | −3.0M | 2.5M |
| 淨利率 | – | -423.0% | -154.4% | -162.1% | -466.3% | -1,273.6% | -119.8% | -187.5% | -192.3% | -265.3% | -1,157.6% | 329.9% |
| 稀釋 EPS | -0.09-69% | -0.16-60% | 0.02-108% | -0.12-52% | -0.29+7% | -0.40+25% | -0.26-24% | -0.25-186% | -0.27 | -0.32 | -0.34 | 0.29 |
| 稀釋股數 | 19.3M | 19.3M | 15.3M | 16.8M | 14.0M | 11.1M | 8.9M | 8.9M | 8.9M | 8.8M | 8.8M | 8.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 11.3M | 14.9M | 16.1M | 17.6M | 10.5M | 13.7M | 9.0M | 7.8M | 11.3M | 15.1M | 17.5M | 18.1M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 14.6M | 17.4M | 19.1M | 21.7M | 14.8M | 17.0M | 10.9M | 11.7M | 14.1M | 17.1M | 19.5M | 22.0M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 2.4M | 3.6M | 2.3M | 3.3M | 4.3M | 2.5M | 3.5M | 2.0M | 2.3M | 3.1M | 2.8M | 2.9M |
| 股東權益 | 12.2M | 13.8M | 16.8M | 18.4M | 10.5M | 14.5M | 7.4M | 9.7M | 11.8M | 14.1M | 16.7M | 19.0M |
| 負債比 | 16.6% | 20.9% | 11.9% | 15.4% | 29.0% | 14.7% | 31.7% | 16.9% | 16.3% | 18.0% | 14.3% | 13.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −1.4M-74% | – | – | – | −5.5M | – | – | −3.8M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 6.2M
| Grant | 3.5M | 57.3% | -46.2% |
|---|---|---|---|
| National Institutes Of Health Small Business Innovation Research For Lymphoma Grant | 665K | 10.7% | 0.0% |
| Cprit Pancreatic Grant | 574K | 9.3% | – |
| National Institutes Of Health Small Business Innovation Research | 472K | 7.6% | -51.9% |
| National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer | 426K | 6.9% | +5831.0% |
| National Institutes Of Health National Cancer Institute Grant | 391K | 6.3% | +6621.1% |
| Fda Grant | 118K | 1.9% | -77.2% |
| Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia 小計 | 900K | 14.5% | -79.6% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 3.5M | -46.2% | −12.2M | -343.0% | -0.79 | – |
| FY2024 | 6.6M | +99.1% | −10.7M | -162.8% | -1.19 | – |
| FY2023 | 3.3M | -5.8% | −8.2M | -248.8% | -0.94 | – |
| FY2022 | 3.5M | – | −29.9M | -851.9% | -3.58 | – |
| FY2021 | 0.00 | -100.0% | −41.9M | –% | -5.47 | – |
| FY2020 | 500K | +134.5% | −28.7M | -5,741.2% | -0.61 | – |
| FY2019 | 213K | +3.5% | −21.4M | -10,050.9% | -0.47 | −18.7M |
| FY2018 | 206K | – | −148M | -71,826.3% | -7.75 | −14.6M |